Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
1.170
+0.010 (0.86%)
At close: Mar 28, 2025, 4:00 PM
1.209
+0.039 (3.30%)
After-hours: Mar 28, 2025, 6:20 PM EDT
Gossamer Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Gossamer Bio stock have an average target of 9.20, with a low estimate of 4.00 and a high estimate of 15. The average target predicts an increase of 686.32% from the current stock price of 1.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Gossamer Bio stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +754.70% | Mar 18, 2025 |
| Wedbush | Wedbush | Buy Reiterates $4 | Buy | Reiterates | $4 | +241.88% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +754.70% | Jan 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +754.70% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +754.70% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
21.53M
from 114.70M
Decreased by -81.23%
Revenue Next Year
54.84M
from 21.53M
Increased by 154.71%
EPS This Year
-0.72
from -0.25
EPS Next Year
-0.48
from -0.72
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.1M | 126.4M | 229.4M | ||
| Avg | 21.5M | 54.8M | 108.0M | ||
| Low | n/a | 16.3M | 51.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -63.3% | 487.2% | 318.4% | ||
| Avg | -81.2% | 154.7% | 97.0% | ||
| Low | - | -24.1% | -6.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.55 | -0.19 | 0.37 | ||
| Avg | -0.72 | -0.48 | -0.15 | ||
| Low | -0.93 | -0.77 | -0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.